|
Delayed
Japan Exchange
02:30:00 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 5,069.00 JPY | -0.65% |
|
+1.75% | +8.78% |
| 10-28 | Biogen tops quarterly estimates on rare-disease drug strength | RE |
| 10-28 | Biogen beats third-quarter results on strength in rare disease drugs | RE |
| Market Cap | 1,429B 9.05B 8.12B 7.5B 6.8B 12.66B 862B 12.85B 88.95B 35.68B 452B 33.98B 33.26B | P/E 2027 * |
24.9x | P/E 2028 * | 21x |
|---|---|---|---|---|---|
| Enterprise Value | 1,345B 8.52B 7.64B 7.06B 6.4B 11.92B 811B 12.09B 83.7B 33.58B 426B 31.97B 31.3B | EV / Sales 2027 * |
1.47x | EV / Sales 2028 * | 1.37x |
| Free-Float |
94.68% | Yield 2027 * |
3.23% | Yield 2028 * | 3.19% |
| Markets | Quality | ||
|---|---|---|---|
Japan Exchange
| 4523 | Delayed | |
Deutsche Boerse AG
| EII | Delayed | |
|
Tradegate
| EII | Real-time | |
|
OTC Markets
| ESALF | Delayed | |
|
Boerse Muenchen
| EII | Real-time | |
|
Börse Stuttgart
| EII | Delayed |
Last Transcript: Eisai Co., Ltd.
| 1 day | -0.65% | ||
| 1 week | +1.75% | ||
| Current month | +4.41% | ||
| 1 month | +2.30% | ||
| 3 months | +6.65% | ||
| 6 months | +10.92% | ||
| Current year | +8.78% |
| 1 week | 4,962 |  | 5,192 |
| 1 month | 4,571 | | 5,192 |
| Current year | 3,660 | | 5,243 |
| 1 year | 3,660 | | 5,243 |
| 3 years | 3,463 | | 8,267 |
| 5 years | 3,463 | | 11,250 |
| 10 years | 3,463 | | 12,765 |
| Manager | Title | Age | Since |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 78 | 2003-05-31 |
Takuya Oyama
DFI | Director of Finance/CFO | 49 | 2025-12-31 |
Keisuke Naito
COO | Chief Operating Officer | 38 | 2024-06-13 |
| Director | Title | Age | Since |
|---|---|---|---|
Haruo Naito
BRD | Director/Board Member | 78 | 1983-05-31 |
Kenta Takahashi
BRD | Director/Board Member | 67 | 2024-06-13 |
Yasushi Okada
BRD | Director/Board Member | 68 | 2025-05-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.65% | +1.75% | +9.93% | -36.96% | 9.11B | |
| +0.50% | +0.36% | +55.89% | +129.96% | 1,143B | |
| +0.86% | +4.50% | +42.43% | +86.15% | 647B | |
| -0.14% | -1.07% | +25.42% | +105.85% | 506B | |
| -0.05% | +2.28% | +49.14% | +67.74% | 384B | |
| -0.63% | -4.97% | +60.15% | +37.06% | 350B | |
| +0.34% | +2.15% | +25.26% | +54.27% | 293B | |
| -0.45% | +1.16% | +1.74% | +26.08% | 265B | |
| +0.87% | +2.94% | +55.18% | +72.74% | 242B | |
| +0.08% | +1.72% | +32.15% | +107.78% | 197B | |
| Average | +0.19% | +1.00% | +35.73% | +65.07% | 403.66B | |
| Weighted average by Cap. | +0.35% | +0.71% | +42.56% | +88.73% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 914B 5.79B 5.2B 4.8B 4.35B 8.1B 551B 8.22B 56.92B 22.83B 289B 21.74B 21.29B | 972B 6.16B 5.52B 5.1B 4.62B 8.61B 586B 8.74B 60.5B 24.27B 308B 23.11B 22.63B |
| Net income | 57.94B 367M 329M 304M 276M 513M 34.93B 521M 3.61B 1.45B 18.34B 1.38B 1.35B | 68.25B 432M 388M 358M 325M 605M 41.15B 614M 4.25B 1.7B 21.6B 1.62B 1.59B |
| Net Debt | -84.27B -534M -479M -442M -401M -747M -50.81B -758M -5.25B -2.1B -26.67B -2B -1.96B | -94.04B -596M -534M -493M -447M -833M -56.71B -845M -5.85B -2.35B -29.77B -2.24B -2.19B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-28 | JP¥5,069.00 | -0.65% | 1,070,500 |
| 26-10-27 | JP¥5,102.00 | +0.08% | 1,134,000 |
| 26-10-26 | JP¥5,098.00 | +0.43% | 983,800 |
| 26-10-23 | JP¥5,076.00 | +0.42% | 1,669,900 |
| 26-10-22 | JP¥5,055.00 | +0.16% | 1,470,900 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4523 Stock
Select your edition
All financial news and data tailored to specific country editions
